Elix, Axcelead DDP team up on targeted protein degrader discovery

Elix and Axcelead Drug Discovery Partners have entered a collaborative research agreement to develop new AI tools for targeted protein degraders, a drug modality aimed at hard-to-treat targets. The companies say the effort will combine Elix’s AI design platform with Axcelead DDP’s proprietary data, assay work and drug discovery expertise.

Why it matters: - Targeted protein degraders are designed to address drug targets that have been difficult to reach with conventional discovery methods. - The collaboration aims to improve drug discovery efficiency and raise the odds of success in TPD research. - The companies also intend to turn the resulting technologies into solutions for pharmaceutical and biotech clients worldwide.

What happened: - Elix, Inc. and Axcelead Drug Discovery Partners, Inc. announced a collaborative research agreement on Sept. 9, 2026. - The agreement focuses on the discovery of novel targeted protein degraders. - The companies will combine AI drug discovery technologies with drug discovery expertise. - Elix is based in Tokyo, and Axcelead DDP is based in Fujisawa, Kanagawa, Japan.

The details: - Elix develops and provides Elix Discovery™, an integrated AI drug discovery platform. - Elix uses multiple molecular generative models, including proprietary in-house technologies, to design novel molecules with medicinal chemist input. - Elix also offers collaborative research and technology development with pharmaceutical and biotechnology companies. - Axcelead DDP supports drug discovery organizations with a platform built from researchers, technologies, facilities and proprietary drug discovery data inherited from a major pharmaceutical company. - Axcelead DDP also strengthens its platform through strategic external partnerships. - The collaboration will use Axcelead DDP’s molecular structure information, proprietary assay data and drug discovery expertise together with Elix’s AI-based molecular design and predictive technologies. - The companies plan to develop new AI technologies for drug discovery through the joint work. - The newly developed models will be applied to Axcelead DDP’s TPD research platform. - The companies expect the effort to improve discovery efficiency and increase the probability of success. - The collaboration is also intended to support new solutions for pharmaceutical and biotechnology companies worldwide. - Elix’s public website is here. - Axcelead DDP’s public website is here. - Elix’s LinkedIn page is here.

Between the lines: - The deal shows how AI drug discovery companies and traditional research platforms are pairing to tackle harder targets. - The emphasis on data, assay development and feedback loops suggests the partnership is aiming to improve both prediction and experimental validation. - Axcelead DDP’s quote points to TPDs as one of the more promising next-generation small-molecule modalities. - Elix’s statement suggests the companies see iterative AI-plus-lab workflows as central to making TPD discovery more productive.

What's next: - The companies will jointly build and test new AI models for TPD discovery. - Those models will be folded into Axcelead DDP’s research platform. - The partners plan to use the resulting technology and insights to support future drug discovery efforts for external customers. - Elix and Axcelead DDP did not disclose financial terms or a timeline for the collaboration.